Stock Events

Stock Events

NovoCure 

$17.99
152
+$0.10+0.56% Thursday 19:59
-$0.78-4.34%Thursday 21:50After hours

Statistics

Day High
18.01
Day Low
17.97
52W High
21.45
52W Low
9.82
Volume
18,212
Avg. Volume
-
Mkt Cap
2.09B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

22OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.62
-0.46
-0.29
-0.13
Expected EPS
-0.244867
Actual EPS
N/A

Financials

-20.79%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
655.35MRevenue
-136.23MNet Income

Analyst Ratings

25.20Average Price Target
The highest estimate is 52.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
40%
Hold
60%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVCR. It's not an investment recommendation.
NVIDIA
28
NVDA
Microsoft
26
MSFT
Amazon
21
AMZN
Apple
20
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Zimmer Biomet
ZBH
Mkt Cap19.26B
Zimmer Biomet Holdings, Inc. provides medical devices in orthopedics, a different approach but still in the competitive landscape of comprehensive cancer care solutions.
Intuitive Surgical
ISRG
Mkt Cap133.83B
Intuitive Surgical, Inc. offers robotic-assisted surgical systems, indirectly competing with NovoCure by providing alternative cancer treatment methods.
Medtronic
MDT
Mkt Cap119.49B
Medtronic plc offers medical technologies, services, and solutions, including cancer treatments, competing in the broader oncology market.
Boston Scientific
BSX
Mkt Cap73B
Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties, including oncology.
Stryker
SYK
Mkt Cap126.37B
Stryker Corporation specializes in medical technologies, including surgical equipment and neurotechnology products that can be used in cancer treatments.
Abbvie
ABBV
Mkt Cap468.22B
AbbVie Inc. is a research-based biopharmaceutical company with a strong portfolio in oncology, directly competing in the cancer treatment market.
Merck
MRK
Mkt Cap376.37B
Merck & Co., Inc. is known for its pharmaceutical products for treating cancer, making it a competitor in the oncology sector.
Pfizer
PFE
Mkt Cap159.99B
Pfizer Inc. is a global biopharmaceutical company with a broad range of oncology treatments, competing in the cancer care market.
Johnson & Johnson
JNJ
Mkt Cap651.25B
Johnson & Johnson engages in the research and development, manufacture, and sale of a broad range of products in the health care field, including cancer treatments.

About

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Show more...
CEO
Frank Leonard
Employees
1605
Country
United Kingdom
ISIN
JE00BYSS4X48
WKN
000A140ML

Listings

F
DE
038.F
MX
MX
NVCRN.MX
STU
DE
038.STU
MU
DE
038.MU

0 Comments

Share your thoughts

FAQ

What is NovoCure stock price today?▼
The current price of NVCR is $17.99 USD — it has increased by +0.56% in the past 24 hours. Watch NovoCure stock price performance more closely on the chart.
What is NovoCure stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange NovoCure stocks are traded under the ticker NVCR.
Is NovoCure stock price growing?▼
NVCR stock has risen by +5.2% compared to the previous week, the month change is a +10.3% rise, over the last year NovoCure has showed a +49.6% increase.
What is NovoCure market cap?▼
Today NovoCure has the market capitalization of 2.09B
When is the next NovoCure earnings date?▼
NovoCure is going to release the next earnings report on October 22, 2026.
What were NovoCure earnings last quarter?▼
NVCR earnings for the last quarter are -0.13 USD per share, whereas the estimation was -0.33 USD resulting in a +60.79% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is NovoCure revenue for the last year?▼
NovoCure revenue for the last year amounts to 655.35M USD.
What is NovoCure net income for the last year?▼
NVCR net income for the last year is -136.23M USD.
How many employees does NovoCure have?▼
As of August 28, 2026, the company has 1,605 employees.
In which sector is NovoCure located?▼
NovoCure operates in the Health & Wellness sector.
When did NovoCure complete a stock split?▼
NovoCure has not had any recent stock splits.
Where is NovoCure headquartered?▼
NovoCure is headquartered in ST. HELIER, United Kingdom.